HK Stock Market Move | TRANSTHERA-B(02617) rises more than 9% in early trading. Prior to this, the approval of Tenofovir Alafenamide Tablets was included in the list of priority review varieties by the National Medical Products Administration.

TRANSTHERA-B(02617) rose more than 9% in early trading, up 4.9% as of the time of writing, at 179.7 Hong Kong dollars, with a turnover of 77.964 million Hong Kong dollars. On the news front, TRANSTHERA-B previously announced that its drug Tengotinib tablets have been approved by the Chinese National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for inclusion in the priority review list. It is intended for the treatment of advanced, metastatic, or unresectable bile duct cancer in adults who have previously received at least one systemic treatment and FGFR inhibitor therapy. Tengotinib has been granted breakthrough therapy designation by the NMPA for the treatment of bile duct cancer. In addition, TRANSTHERA-B recently announced that the exploratory Phase 2 clinical trial results of its core product Tengotinib for bile duct cancer in the United States have been published in "The Lancet Gastroenterology & Hepatology" (impact factor 38.6). In this Phase 2, open-label, multicenter study (NCT04919642), eligible patients with bile duct cancer include those with FGFR2 fusions who are primary or acquired resistant to FGFR inhibitors, or those with other FGFR gene alterations, as well as patients with FGFR wild-type. Tengotinib can overcome acquired resistance to FGFR inhibitors in FGFR2 fusion-positive bile duct cancer patients and demonstrates anti-tumor activity in bile duct cancer patients with other FGFR gene alterations.